Vascular Pharmaceuticals

About Vascular Pharmaceuticals

Vascular Pharmaceuticals is at the forefront of developing groundbreaking treatments for diabetic nephropathy, a severe kidney disease affecting individuals with Type 1 and Type 2 diabetes. Operating in the biopharmaceutical sector, the company is dedicated to addressing a significant unmet medical need, as there is currently no cure for this condition. Vascular Pharmaceuticals' lead candidate, VPI 2960B, is undergoing Phase 2 clinical trials, showing promise in stopping and potentially reversing the progression of diabetic nephropathy based on animal model studies. The company serves patients with diabetes, particularly those suffering from kidney complications, and operates within the healthcare and pharmaceutical markets. Its business model revolves around the research, development, and eventual commercialization of innovative therapeutic solutions. Revenue generation is anticipated through the successful development and market introduction of VPI 2960B, as well as potential partnerships and licensing agreements.